Clinical Trials Detalhe
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Visão Geral
Gender
ALL
Idade
N/A
Fase
PHASE2
Tipo de Estudo
INTERVENTIONAL
Localização
Hospital Infante D. Pedro; Servico de Oncologia Medica (Aveiro, Portugal)
Hospital Geral; Servico de Pneumologia (Coimbra, Portugal)
IPO de Lisboa; Servico de Pneumologia (Lisbon, Portugal)
Hospital Santo Antonio dos Capuchos;Servico de Oncologia Medica (Lisbon, Portugal)
Hospital de Santa Maria; Servico de Pneumologia (Lisbon, Portugal)
Hospital Pulido Valente; Servico de Pneumologia (Lisbon, Portugal)
IPO do Porto; Servico de Oncologia Medica (Porto, Portugal)
Hospital de Sao Joao; Servico de Pneumologia (Porto, Portugal)
CHVNG/E_Unidade 1; Servico de Pneumologia (Vila Nova de Gaia, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT01260181Sumário
This single arm, open-label study will evaluate the efficacy and safety of erlotinib (Tarceva) in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations.
Condições
Non-Squamous Non-Small Cell Lung Cancer
Elegibilidade
Inclusion Criteria: * Locally advanced or metastatic NSCLC with EGFR mutations * Measurable disease according to RECIST criteria * Adequate hematological, renal and liver function Exclusion Criteria: * Previous chemotherapy or therapy against EGFR for metastatic disease * Symptomatic cerebral metastases * Pre-existing disease of the lung parenchyma such as lung fibrosis, lymphangitic carcinomatosis * History of another malignancy except for carcinoma in-situ of the cervix, adequately treated basal cell skin carcinoma, or radically treated prostate carcinoma with good prognosis * Concomitant use of coumarins